MEDICAL INTELLIGENCE
(continued from page 41)
targeted therapy (TT) following cytoreductive nephrectomy
for metastatic renal cell carcinoma (mRCC) is not
associated with worse survival, according to findings presented
at the American Urological Association 2018 annual
meeting. In a retrospective observational study that
included 2716 patients with mRCC treated with both
cytoreductive nephrectomy and TT, Solomon Woldu, MD,
of the University of Texas Southwestern Medical Center in
Dallas, and colleagues found that the risk of death among
patients with moderately delayed, delayed, and late TT did
not differ significantly from patients who had early TT.
The investigators defined TT delivered within 2 months
of mRCC diagnosis as early (1255 patients, 46.2%). They
considered TT delivered in 2 to 4 months, 4 to 6 months,
and more than 6 months to be moderately delayed (1072
patients, 39.5%), delayed 284 patients, 10.5%), and late (105
patients, 3.9%), respectively. The median time from mRCC
diagnosis to initiation of TT was 2.1 months.
The investigators acknowledged that their study is
limited by the study design and potential selection bias,
but noted that the findings are consistent with the idea
that, among carefully selected patients, initial observation
might not compromise outcomes.
Partial vs radical nephrectomy lowers
elderly patient mortality risk
SAN FRANCISCO—Compared with radical nephrectomy
(RN), partial nephrectomy (PN) for small renal tumors in
elderly patients is associated with a lower risk of cancerspecific
and other-cause mortality, researchers reported at
the American Urological Association 2018 annual meeting.
Using 2004–2014 data from the Surveillance, Epidemiology
and End Results (SEER) registry, Michele Marchioni,
MD, of SS Annunziata Hospital “G.D’Annunzio” University of
62 Kidney Cancer Journal
Chieti, Chieti, Italy, and colleagues identified 4541 surgically
treated patients aged 75 years or older who had nonmetastatic
pT1a renal cell carcinoma. After they matched 1
RN to 1 PN patient by propensity score, the investigators
had a study cohort of 2826 patients.
In multivariate analysis, PN was associated with a sig-
”nificant 36% and 33% decreased risk of cancer-specific and
other-cause mortality, respectively. The investigators found
no difference in 30-day mortality risk. The authors concluded
that PN should be given strong consideration in the
treatment of small renal tumors, even for elderly patients.
Global kidney cancer drugs market
forecast for 2017-2025
DUBLIN—The global kidney cancer drug market was valued
at US$ 3,302.3 million in 2016, and is expected to reach
US$ 6,441.9 million by 2025, expanding at 8.1% from 2017
to 2025, according to data from ResearchAndMarkets.com
The incidence of renal cell cancer is observed highest in
Northern America and Europe. Almost 59% of kidney cancer
cases are observed in developed countries. Thus, rising
incidence of kidney cancer and entry of novel drug treatments
are the key factors contributing to the growth of the
kidney cancer drug market. Sutent dominates the global
kidney cancer/renal cell carcinoma drugs market. North
America dominates the global kidney cancer drugs market
followed by Europe.
Rise in incidence of renal cancer, increasing geriatric
population and novel drug treatment are key drivers for the
growth of the kidney cancer drug market in North America.
Asia Pacific is the fastest growing regional market for kidney
cancer drugs with the highest compound annual growth
rate in the forecast period. Improvements in diagnostic
technology, a rise in aged population and low cost production
of drugs are some of the key factors contributing
to the growth of the market in the Asia Pacific region. KCJ
/ResearchAndMarkets.com